spesolimab · Spevigo

Monoclonal antibody

Also known as BI 655130

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis (label: generalized pustular psoriasis)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hidradenitis Suppurativa · Phase 2/3 · investigational in the US

Also approved (5)
CA
  • Spevigo (spesolimab injection/spesolimab for injection) is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.
Product first approved 2023Health Canada
EU
  • Treatment of generalised pustular psoriasis (GPP) flares and prevention of GPP flares, adults and adolescents 12 years and older (conditional authorisation; holder LEO Pharma A/S)
  • Treatment of generalised pustular psoriasis (GPP) flares and prevention of GPP flares, adults and adolescents 12 years and older (conditional authorisation)
Product first approved 2022EMA
JP
  • Acute symptoms of generalised pustular psoriasis (GPP), intravenous Spevigo 450 mg
Product first approved 2022nk.jiho.jp
CN
  • Expanded approval: reduction of occurrence of GPP in adolescents 12 years and older (at least 40 kg) and adults. An earlier first China approval exists; its date was not found. The month is that of the Boehringer release that calls this approval recent.
biospace.com
Featured evidence outside this drug's tracked markets:NCT06624670 · Pyoderma Gangrenosum · Phase 3 · ungraded

Development in Crohn's Disease stopped for reasons the sponsor has not stated. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Psoriasis
NCT05239039 · Boehringer Ingelheim
2022-03-15 – 2023-07-17 · Generalized Pustular Psoriasis
What this study did
NCT05200247 · Boehringer Ingelheim
2022-02-17 – 2023-03-20 · Generalized Pustular Psoriasis
What this study did
Other / comorbidity
NCT06624670 · LEO Pharma
2025-02-05 – 2028-08-19 · Pyoderma Gangrenosum
What this study did
Phase 2/3 (4)
Hidradenitis Suppurativa
NCT06241573 · Boehringer Ingelheim
2024-05-08 – 2025-04-11 · Hidradenitis Suppurativa (HS)
What this study did
NCT05819398 · Boehringer Ingelheim
2023-04-17 – 2025-03-31 · Hidradenitis Suppurativa
What this study did
Other / comorbidity
NCT05856526 · Boehringer Ingelheim
2023-06-12 – 2025-07-31 · Netherton Syndrome
What this study did
Phase 2 (17)
Hidradenitis Suppurativa
NCT04876391 · Boehringer Ingelheim
2021-08-24 – 2024-04-26 · Hidradenitis Suppurativa
What this study did
NCT04762277 · Boehringer Ingelheim
2021-04-06 – 2022-04-21 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT03886246 · LEO Pharma
2019-05-29 – 2028-04-27 · Generalized Pustular Psoriasis
What this study did
NCT03135548 · Boehringer Ingelheim
2017-05-30 – 2018-11-14 · Psoriasis
What this study did
Other / comorbidity
NCT06092216 · Icahn School of Medicine at Mount Sinai
2023-09-23 – 2025-01-14 · Pyoderma Gangrenosum
What this study did
NCT04493424 · Boehringer Ingelheim
2020-09-04 – 2023-05-15 · Palmoplantar Pustulosis
What this study did
NCT03648541 · Boehringer Ingelheim
2018-10-29 – 2023-05-03 · Colitis, Ulcerative
What this study did
NCT04362254 · Boehringer Ingelheim
2020-05-15 – 2022-09-23 · Crohn Disease
What this study did
NCT03752970 · Boehringer Ingelheim
2019-02-05 – 2022-07-04 · Crohn Disease
What this study did
NCT05013385 · Boehringer Ingelheim
2021-11-09 – 2022-05-31 · Fibrostenotic Crohn´s Disease
What this study did
NCT04086121 · Boehringer Ingelheim
2019-09-24 – 2022-02-23 · Dermatitis, Atopic
What this study did
NCT04015518 · Boehringer Ingelheim
2019-07-31 – 2021-07-28 · Palmoplantar Pustulosis (PPP)
What this study did
Phase 1 (8)
Psoriasis
NCT02978690 · Boehringer Ingelheim
2016-12-19 – 2018-01-10 · Psoriasis
What this study did
Other / comorbidity
NCT06520514 · Boehringer Ingelheim
2024-08-07 – 2025-02-04 · Healthy
What this study did
NCT04390568 · Boehringer Ingelheim
2020-05-21 – 2021-06-04 · Healthy
What this study did
NCT03617835 · Boehringer Ingelheim
2018-08-16 – 2019-06-03 · Healthy
What this study did
NCT03100903 · Boehringer Ingelheim
2017-04-24 – 2018-01-10 · Healthy
What this study did
NCT03123094 · Boehringer Ingelheim
2017-05-16 – 2018-01-04 · Healthy
What this study did
NCT02852824 · Boehringer Ingelheim
2016-08-10 – 2017-08-01 · Healthy
What this study did
NCT02525679 · Boehringer Ingelheim
2015-09-14 – 2016-05-27 · Healthy
What this study did
Phase 4 (1)
Psoriasis
NCT06013969 · LEO Pharma
2023-10-22 – 2026-09-02 · Generalized Pustular Psoriasis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hidradenitis Suppurativa: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Spesolimab (Spevigo): this drugPhase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FPartial signal
NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results).
NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Partial signal
NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants
NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants
LutikizumabPhase 3Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2/3Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
AbdakibartPhase 2Monoclonal antibodyIL-1 betanot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
EltrekibartPhase 2Monoclonal antibodyCXCR1/2not yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ORKA-002Phase 2Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
SAR442970Phase 2——not yet gradedNo reviewed efficacy summary in this indication
SAR445399Phase 2Monoclonal antibodyIL-1R3 (IL1RAP)not yet gradedNo reviewed efficacy summary in this indication
SPY072Phase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-1451
Phase 1(overall)
UndisclosedIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
SAR447971
Phase 1(overall)
Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Spevigo (spesolimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
Phase 2PsoriasisActive not recruiting
Est. primary completion 2027-09-30 · NCT03886246 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Pyoderma GangrenosumRecruiting
Est. primary completion 2027-11-12 · NCT06624670 · CT.gov ↗
What to watch

See the full readout calendar ↗